Abiopharma

RUNWAY GROWTH FINANCE CORP. (RWAY) Reports the reporting period Financial Results RUNWAY GROWTH FINANCE CORP. (RWAY) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: (17,483
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 2312
  • 0 million of our outstanding shares of common stock. Under the New Repurchase Program, purchases may be made at management’s discretion from time to time in open
  • market transactions, in accordance with all applicable securities laws and regulations. If not renewed, the New Repurchase Program will terminate upon the earlier of (i) May 7, 2027 or (ii) the repurchase of $
  • 0 million of our outstanding shares of common stock.Retirement and Appointment of Certain OfficersThe CompanyOn May 5, 2026, Thomas B. Raterman notified our Board of Directors that he would retire from his positions as our Chief Operating Officer, Chief Financial Officer, Treasurer and Corporate Secretary effective as of the close of business on June 30, 2026, at which time he will become Vice Chairman of RGC. In that role, he will focus on strategic initiatives that include portfolio optimization, platform